The biotechnology industry is undergoing a profound digital transformation, with artificial intelligence (AI), cloud computing and real-time analytics reshaping drug discovery, personalised medicine and healthcare delivery.
Early intervention in neurodegenerative diseases, such as Alzheimer’s, offers the potential to slow or prevent disease progression, and increase success rates for clinical development.